Abstracts | 47 of oxytocin. Moreover, the degree of neural overlap was significantly low in ASD model mice. These findings offer insight into our understanding of the neural mechanisms of empathy and the development of therapeutic treatment of ASD.
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Enhancement of the accumbal dopamine release by the gene mutation of synaptic vesicle protein 2A (Sv2a
L174Q

)
Kentaro Tokudome, Kazuki Fukuda, Azuki Hashimoto, Yuki Hiraoka, Yumiko Iguchi, Ayako Ikari, Masato Kinboshi, Naofumi Kunisawa, Yukihiro Ohno, Tadao Serikawa, Saki Shimizu, Takafumi Suguhara, Kentaro Tokudome Osaka University of Pharmaceutical Sciences, Japan Abstract SV2A is a prototype synaptic vesicles protein and regulates action potential-dependent synaptic release of neurotransmitter. We previously reported that SV2A mutant rats, carrying a missense mutation (L174Q) in the Sv2a gene, showed impaired hippocampal GABA release and enhanced seizure susceptibility. Since recent studies reported a significant association of genetic SV2A polymorphism with schizophrenia (Schizophr. Res., 141, 262, 2012) , we performed in vivo microdialysis and behavioral studies using the SV2A mutant rats to evaluate the role of SV2A in controlling accumbal dopaminergic neurotransmission. In vivo microdialysis studies showed that the Sv2a gene mutation significantly increased both depolarization (100 mM K + )-and methamphetamine (MAP, 100 µM)-induced dopamine release in the nucleus accumbens (NAc) without affecting basal dopamine release and dopamine contents. In behavioral studies, MAP (1 mg/kg, i.p.)-induced hyperlocomotion was significantly augmented by the Sv2a gene mutation. Haloperidol (0.5 mg/kg, i.p.) completely suppressed MAP-induced hyperlocomotion both in SV2A mutant and control (F344) rats. In addition, development of locomotor sensitization (reverse tolerance) to repeated MAP treatments (0.3 mg/kg/day, 12 days) was significant enhanced in SV2A mutant rats as compared to F344 rats. The present results suggest that dysfunction of SV2A by the missense mutation (L174Q) enhances synaptic dopamine release in the NAc, which may be linked to vulnerability to psychotic disorders.
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Apathy and striatal dopamine receptor type 2-expressing medium spiny neurons
Iku Tsutsui-Kimura, Hiroyuki Takieu, Kenji F. Tanaka Keio University School of Medicine, Japan
Abstract Apathy is defined as the quantitative reduction of voluntary, goal-directed behaviors. It often coincides with lesions or dysfunction of the cortico-striatal system. However, the underlying neural substrate of apathy is largely unknown. Based on the coincidence of apathy with bilateral striatal lesions or the pre-diagnosis phase of Huntington's disease in which striatal dopamine receptor type 2-expressing medium spiny neurons (D2-MSNs) are particularly degenerated, we hypothesized that bilateral loss-of-function of D2-MSNs cause apathy.
To address this question, we combined time-controllable diphtheria toxin-mediated D2-MSN-specific loss-of-function with food-reinforced instrumental tasks in mice.
Loss-of-function always started in the ventrolateral striatum (VLS) and expanded concentrically day-by-day, enabling our search for the responsible region underlying apathy appearance according to behavioral onset. We found that a loss-of-function of only 17% of a specific cell type (D2-MSN) within a restricted region (VLS) was sufficient to trigger apathy. Termination of diphtheria toxin expression induced a restriction of cell ablation within the VLS, producing a chronic apathy model. We further demonstrated that acute optogenetic inhibition of VLS D2-MSNs resulted in a transient decrease in the instrumental motivation, strengthening the evidence that VLS D2-MSNs mediate apathy.
Taken together, our data demonstrate a key role of VLS D2-MSNs in apathy pathogenesis.
